5 results
diagnosis druginduced sle activation antinxp2dm comparison dermatology dermatomyositis dil erythematosus macrophage mas summary syndrome systemic table
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... #Summary #rheumatology
Drug Induced Lupus vs SLE Drug Induced Lupus (DIL): • Epidemiology: -10% of all lupus cases, drug-dependent,
NPSLE rare, Malar rash ... Discontinuation of causal ... Manifestations: Malar rash ... comparison #table #rheumatology ... #diagnosis #management
Macrophage Activation Syndrome (MAS) Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH) What? A subset of
• Adult-onset Still ... Petechial or purpuric rash ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Anti-NXP-2 Dermatomyositis What? DM with generalized subcutaneous edema Pts have more myalgias, more severe weakness, and an increased prevalence
But can still have ... Muscle atrophy may cause ... positive patients Treatment ... #diagnosis #management ... #rheumatology #
Drug Induced Lupus (DIL) • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
NPSLE rare, Malar rash ... Discontinuation of causal ... #DIL #rheumatology ... #diagnosis #treatment ... #management
No results found for "rash nejm peds causes management treatment rheumatology oncology hematology stills lupus antinxp2"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #rash #nejm #peds #causes #management #treatment #rheumatology #oncology #hematology #stills #lupus #antinxp2